Effects of the glucocorticoid receptor antagonist PT150 on stress-induced fentanyl seeking in male and female rats.


Journal

Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 02 09 2020
accepted: 30 04 2021
pubmed: 20 5 2021
medline: 29 9 2021
entrez: 19 5 2021
Statut: ppublish

Résumé

Opioid use disorder (OUD) is highly comorbid with stress-related disorders, and stress can serve as a trigger for reinstatement of drug seeking. Glucocorticoid receptor (GR) antagonists such as mifepristone (RU-486) may be effective against stress-induced drug seeking. In the current study, PT150 (formerly ORG-34517), a more selective GR antagonist, was tested using two models of stress-induced drug seeking, namely footshock and yohimbine. Adult male and female Sprague-Dawley rats were trained to self-administer fentanyl (2.5 μg/kg/infusion, i.v.) in a model of escalation. Rats then received 7 days of abstinence, followed by extinction; PT150 (0, 50 or 100 mg/kg in Nutella®; p.o.) treatment started on the first day of extinction training and continued daily until the end of the study. Following 14 days of extinction, rats were tested for reinstatement following footshock and yohimbine (0, 1, or 2 mg/kg; i.p.), tested in counterbalanced order; PT150 or placebo treatment occurred prior to each extinction and reinstatement session. Prior to initiation of PT150 treatment, females self-administered greater levels of fentanyl during 1-h sessions compared to males; however, when switched to 6-h sessions, males and females self-administered similar levels of fentanyl and showed a similar escalation of intake over time. PT150 had no effect on extinction of self-administration. While both footshock and yohimbine reinstated fentanyl seeking, only footshock-induced reinstatement was decreased by PT150 (50 and 100 mg/kg). The effect of PT150 on footshock-induced reinstatement was driven primarily by males. The glucocorticoid antagonist PT150 reduces shock-induced fentanyl seeking, suggesting it may be effective against stress-induced relapse, although the sex difference in response may need further exploration.

Identifiants

pubmed: 34008048
doi: 10.1007/s00213-021-05865-0
pii: 10.1007/s00213-021-05865-0
pmc: PMC10323366
mid: NIHMS1912565
doi:

Substances chimiques

Receptors, Glucocorticoid 0
Yohimbine 2Y49VWD90Q
Fentanyl UF599785JZ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2439-2447

Subventions

Organisme : NIDA NIH HHS
ID : R21 DA041755
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA016176
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA053070
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Neurosci Biobehav Rev. 2003 Aug;27(5):457-91
pubmed: 14505687
J Addict Dis. 2016 Jul-Sep;35(3):169-79
pubmed: 27010975
Gynecol Endocrinol. 2014 Mar;30(3):169-73
pubmed: 24205903
Neuropsychopharmacology. 2015 Jan;40(2):421-8
pubmed: 25060491
Behav Brain Res. 2014 May 1;264:43-50
pubmed: 24508237
Drug Alcohol Depend. 2015 Sep 1;154:100-4
pubmed: 26143299
N Engl J Med. 2017 Feb 16;376(7):605-607
pubmed: 28199808
Front Behav Neurosci. 2020 May 20;14:74
pubmed: 32508605
Behav Neurosci. 2005 Oct;119(5):1215-1221
pubmed: 16300428
Ann N Y Acad Sci. 2008 Dec;1148:536-41
pubmed: 19120154
Neuropsychopharmacology. 2012 Mar;37(4):906-18
pubmed: 22048462
Psychopharmacology (Berl). 1999 May;144(1):77-82
pubmed: 10379627
Neuropsychopharmacol Rep. 2018 Sep;38(3):105-116
pubmed: 30175522
Mol Psychiatry. 2012 Dec;17(12):1283-94
pubmed: 21946917
Mil Med. 2014 Aug;179(8):885-90
pubmed: 25102531
Neuropsychopharmacology. 2003 Jun;28(6):1056-67
pubmed: 12700716
Neuropsychopharmacology. 2016 Jan;41(1):335-56
pubmed: 25976297
J Psychosoc Nurs Ment Health Serv. 2013 Jun;51(6):11-4
pubmed: 23814820
Addict Biol. 2017 Mar;22(2):342-353
pubmed: 26598419
J Neuroendocrinol. 2001 Oct;13(10):875-86
pubmed: 11679056
Science. 1998 Oct 9;282(5387):298-300
pubmed: 9765157
Stress. 2004 Dec;7(4):233-41
pubmed: 16019588
Alcohol Clin Exp Res. 2013 Aug;37(8):1417-23
pubmed: 23527822
Exp Clin Psychopharmacol. 2007 Oct;15(5):472-80
pubmed: 17924781
Psychopharmacology (Berl). 2021 Apr;238(4):969-978
pubmed: 33404736
Addict Biol. 2015 Jul;20(4):690-700
pubmed: 25065697
Exp Clin Psychopharmacol. 2007 Oct;15(5):445-52
pubmed: 17924778
Psychopharmacology (Berl). 2017 Dec;234(23-24):3499-3506
pubmed: 28916995
Exp Clin Psychopharmacol. 2018 Aug;26(4):329-334
pubmed: 29878800
Psychopharmacology (Berl). 2020 Dec;237(12):3689-3702
pubmed: 32840668
Neuropsychopharmacology. 2020 Nov;45(12):1974-1985
pubmed: 32303052
J Clin Invest. 2015 Aug 3;125(8):3193-7
pubmed: 26121746

Auteurs

Lindsey R Hammerslag (LR)

Department of Psychology, University of Kentucky, BBSRB Room 447, Lexington, KY, 40536-0509, USA.

Emily D Denehy (ED)

Department of Psychology, University of Kentucky, BBSRB Room 447, Lexington, KY, 40536-0509, USA.

Benjamin Carper (B)

Research Triangle Institute, Research Triangle Park, Durham, NC, USA.

Tracy L Nolen (TL)

Research Triangle Institute, Research Triangle Park, Durham, NC, USA.

Mark A Prendergast (MA)

Department of Psychology, University of Kentucky, BBSRB Room 447, Lexington, KY, 40536-0509, USA.

Michael T Bardo (MT)

Department of Psychology, University of Kentucky, BBSRB Room 447, Lexington, KY, 40536-0509, USA. mbardo@uky.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH